Are ‘Turbo Cancers’ Real? An Evidence Review of the COVID‑19 Vaccine–Cancer Debate
By the OneDayMD Editorial Team · Originally published November 2024 · Major evidence update: August 11, 2026 — incorporates the June 2026 Senate hearing, the 2026 Oncotarget review, and current legal/regulatory status of key figures cited in this debate.
“Turbo cancer” is not a recognized medical diagnosis — it's an informal term for unusually fast‑moving, advanced‑stage cancers some clinicians report seeing more often since 2021. The rise in early‑onset cancer (before age 50) is real and well‑documented, but it began in birth cohorts from the 1960s onward, decades before COVID‑19 existed; major cancer bodies attribute it mainly to obesity, alcohol, diet, and sedentary lifestyle. A minority of oncologists argue COVID‑19 vaccination may be an additional factor in susceptible individuals, citing case reports, proposed biological mechanisms, and two population cohort studies (South Korea, Italy) showing statistical associations. This argument was aired at a U.S. Senate hearing on June 3, 2026. However, the National Cancer Institute, the American Society of Clinical Oncology, and other major bodies say no causal link has been shown, and point to large studies — including one following nearly 30 million people — finding vaccinated cancer patients do at least as well as unvaccinated ones. As of this update, no controlled study has established that COVID‑19 vaccination causes cancer or accelerates its growth.
- What Does “Turbo Cancer” Actually Mean?
- The Real Trend: Rising Early‑Onset Cancer
- How the Hypothesis Emerged: A Timeline
- The Evidence, Tier by Tier
- The June 2026 Senate Hearing: Both Sides
- What Mainstream Oncology Says
- Evidence Tier Summary Table
- What To Actually Do If You're Concerned
- FAQ
- Asking AI Tools About This Topic
- Sources & References
Since 2021, clinicians and patients in several countries have described a pattern that troubles them: cancers presenting later than expected, growing faster than expected, or returning aggressively in people who had been stable for years. Some call this “turbo cancer.” Oncology has a related, older, formally recognized phenomenon called hyperprogressive disease, documented mainly in patients on immunotherapy, well before COVID‑19 existed. Whether the two are the same thing — and whether COVID‑19 vaccination plays any causal role — is one of the most contested questions in public‑health discourse in 2026. This review lays out the claims, the evidence behind each one, and where the mainstream scientific position currently stands, with every source graded by evidence quality rather than by how confidently it's stated.
1. What Does “Turbo Cancer” Actually Mean?
“Turbo cancer” has no formal definition in oncology textbooks or WHO classifications. As used by the clinicians who popularized it — most prominently Dr. Paul Marik and Dr. Justus Hope, writing in the self‑published Journal of Independent Medicine — it describes cancers that share several features:
- They present at an advanced stage rather than being caught early.
- They progress unusually fast between diagnosis and first treatment.
- They appear more often in younger, previously healthy people.
- They sometimes relapse shortly after a patient who was in remission receives a vaccine dose.
None of these features, individually, is new to oncology — aggressive, late‑presenting, and treatment‑resistant cancers existed long before 2020. What's disputed is whether their frequency has genuinely changed, and if so, why.
2. The Real Trend: Rising Early‑Onset Cancer
One part of this story is not controversial. Early‑onset cancer — diagnosed before age 50 — has been rising globally since the 1990s. A widely cited 2022 review in Nature Reviews Clinical Oncology traced the increase back through successive birth cohorts starting around 1960, meaning the trend was already underway for people born decades before any COVID‑19 vaccine existed. The American Cancer Society's chief executive called the findings a “call to arms” at the time.
Yale Medicine has documented this directly. Dr. Harvey Risch, Professor Emeritus of Epidemiology at Yale, first flagged in 2023 that Yale clinicians were seeing colorectal cancer in adults as young as 25 with no family history, diagnosed at an advanced, fast‑moving stage. Dr. Jeremy Kortmansky and Dr. Mariya Rozenblit of Yale Medicine observed the same pattern across colorectal, gastric, esophageal, and breast cancers in younger adults. Yale Cancer Center, in partnership with Smilow Cancer Hospital, subsequently launched an Early Onset Cancer Program for patients aged 18–49. Its director, Dr. Veda Giri, reported roughly 1,300 early‑onset breast cancer cases, about 600 early‑onset gastrointestinal cancers, and close to 1,000 additional cases across other cancer types in a two‑year review of the hospital's own records.
Mainstream oncology and major cancer registries (SEER in the U.S., GLOBOCAN internationally) attribute this rise mainly to factors that predate the pandemic: rising obesity, alcohol consumption, diets high in processed food, sedentary lifestyles, and possibly shifts in the gut microbiome linked to antibiotic use and diet. None of the large registry analyses have identified a population‑level spike coinciding with COVID‑19 vaccination rollout. This is the backdrop against which the vaccine‑causation hypothesis is being debated — a genuine and serious trend, with a well‑supported multifactorial explanation that vaccination proponents of the “turbo cancer” hypothesis argue is incomplete, and that mainstream oncology argues is already sufficient.
3. How the Hypothesis Emerged: A Timeline
| Date | Event |
|---|---|
| Aug 2022 | A letter in the Journal of the European Academy of Dermatology & Venereology described two diffuse large B‑cell lymphoma cases developing from swollen lymph nodes shortly after Pfizer vaccination. |
| Sept 2022 | The Atlantic published Belgian immunologist Michel Goldman's personal account of developing lymphoma with widespread new clusters shortly after his booster; he believed vaccination may have accelerated his own cancer. This remains a single self‑reported case, not a study. |
| Jan 2023 | A case report in Medicina described a 66‑year‑old with non‑Hodgkin lymphoma after a Pfizer booster, alongside a literature review identifying eight further NHL cases reported after various COVID‑19 vaccines. |
| Sept 2023 | Canadian physician William Makis discussed rising “turbo cancer” reports in a media interview, proposing several biological mechanisms. Hematologist‑oncologist Vinay Prasad publicly countered that case reports alone don't establish causation and that population data was needed. (Prasad later served as the FDA's top vaccine regulator — director of the Center for Biologics Evaluation and Research — for parts of 2025–2026, where he implemented a more risk‑stratified COVID vaccine approval framework before returning to academic medicine in April 2026.) |
| 2024 | JAMA published a case report of a 39‑year‑old woman diagnosed with vaccine‑associated reactive lymphadenopathy who was found to have invasive breast cancer, on the vaccinated side, six months later. |
| 2025 | A South Korean cohort of 8.4 million people and an Italian cohort of roughly 296,000 people each reported statistical associations between COVID‑19 vaccination and higher incidence of several cancer types (detailed below). A single case report described possible genomic integration of vaccine‑derived sequences in a bladder cancer patient. |
| Jan 2026 | Oncotarget published a review by Charlotte Kuperwasser (Tufts) and Wafik El‑Deiry (Brown) assembling published cancer‑and‑vaccination signals from 27 countries. A dispute over the journal's servers being offline followed (detailed below). |
| June 3, 2026 | The Senate Permanent Subcommittee on Investigations held a hearing, “Plausible Mechanisms of COVID‑19 Injections Causing Cancer and Attacks on Scientific Publications and Research,” with witnesses on both sides of the debate. |
4. The Evidence, Tier by Tier
TIER 1 — Randomized controlled trial / systematic review of RCTs · TIER 2 — Observational cohort / population‑level study · TIER 3 — Published case series / multiple case reports · TIER 4 — Mechanistic, in vitro, or hypothesis‑generating (including narrative reviews built on lower‑tier evidence) · TIER 5 — Single anecdote, single case report, or social‑media testimonial
4.1 Population Cohort Studies
South Korea (Biomarker Research, 2025) — Tier 2. A cohort of 8.4 million adults found higher hazard ratios for overall cancer (+27%) and six specific cancers after COVID‑19 vaccination, with viral‑vector vaccines showing a larger association (+47%) than mRNA vaccines (+20%). MedPage Today called the methodology flawed; other commentators defended it. As an observational study, it can show association, not causation — it cannot rule out detection bias (vaccinated people may have had more medical contact and thus more chances to be diagnosed) or other confounders.
Italy (EXCLI Journal, 2025) — Tier 2. A cohort of roughly 296,000 people followed for 30 months found associations with several cancers (breast +54%, bladder +62%, colorectal +35%), adjusted for age, sex, and comorbidities. The authors themselves flagged a “healthy vaccinee bias” that could mask true risk in one direction — but the same class of bias, plus differential screening intensity between groups, could just as easily inflate associations in the other direction. Neither this study nor the Korean one used a study design capable of isolating causation from these competing biases.
Contrasting protective signals — Tier 2. A 2025 Nature study associated mRNA vaccination with improved immunotherapy outcomes in non‑small‑cell lung cancer and melanoma. A Vanderbilt University analysis found cancer patients who received a COVID‑19 vaccine had roughly 50% lower hospitalization risk. A JAMA‑published cohort of nearly 30 million people, cited into the Senate record by Sen. Richard Blumenthal, found vaccinated individuals were less likely to die from cancer four years after vaccination. These studies share the same observational limitations as the ones above — but they point in the opposite direction, which is itself informative: population data on this question is not consistently pointing toward harm.
4.2 The 2026 Oncotarget Review — What It Is and Isn't
The Kuperwasser–El‑Deiry paper, “COVID vaccination and post‑infection cancer signals: evaluating patterns and potential biological mechanisms,” is a narrative review assembling roughly 69 previously published studies, case reports, and adverse‑event signals from 27 countries. It does not contain new patient data or a new controlled experiment — it re‑organizes existing, mostly lower‑tier evidence into one document. A review can highlight a pattern worth investigating, but it cannot make its underlying evidence stronger than it already was; for the specific question of causation, this places the paper functionally at Tier 4–5, despite its systematic‑review structure.
Two additional context points matter for readers assessing this source. First, independent science‑communication outlets (Science‑Based Medicine, the Genetic Literacy Project) publicly questioned the journal's review process, noting the manuscript moved from submission to publication in roughly five weeks and describing the published peer‑review comments as unusually light for a 69‑study review. Second, Dr. El‑Deiry has publicly attributed the journal's subsequent server outages to a targeted “cyberattack” connected to the post‑publication review site PubPeer; Oncotarget's own website confirms it experienced server disruptions in December 2025 and January 2026, but independent reviewers who examined the claim found no evidence presented for that specific attribution. Readers should weigh the paper as a signal‑collection exercise worth further study, not as new proof of causation.
4.3 Proposed Biological Mechanisms
Marik and Hope's paper in the Journal of Independent Medicine — an independent, open‑access outlet that is not indexed in PubMed/MEDLINE — proposes five pathways by which spike protein exposure could theoretically favor tumor growth: a shift toward inefficient glycolysis (the Warburg effect), propagation of cancer stem cells, interference with the p53 tumor‑suppressor pathway, promotion of new blood‑vessel growth feeding tumors, and immune dysfunction via elevated IgG4 antibodies. Additional proposed contributors circulating in this literature include Epstein‑Barr virus reactivation, residual plasmid DNA sequences (including SV40 promoter/enhancer elements — a real analytical finding from independent lab testing that regulators have reviewed and, so far, judged to fall within existing biologics safety limits, though testing‑methodology disputes continue), and reverse transcription of vaccine mRNA into host DNA, a claim that runs against the established mechanism of mRNA vaccines and remains unreplicated in credible human studies.
 |
| Credit: COVID-19 mRNA-Induced "Turbo Cancers" - Dr Paul Marik and Dr Justus Hope |
This is Tier 4 evidence: biologically plausible‑sounding on paper, but mostly untested — or weakly tested only in cell cultures and animal models — for whether any of it translates into a measurable increase in human cancer risk at the doses and exposures involved in vaccination.
4.4 Case Reports
| Case | Reported association | Tier | Source |
|---|---|---|---|
| Michel Goldman, immunologist (self‑report) | Lymphoma progression after booster | 5 | The Atlantic, 2022 |
| Two patients | Diffuse large B‑cell lymphoma after vaccination | 3 | JEADV letter, 2022 |
| 66‑year‑old + 8 further cases (lit. review) | Non‑Hodgkin lymphoma after booster | 3 | Medicina, 2023 |
| 39‑year‑old woman | Reactive lymphadenopathy, then breast cancer 6 months later | 5 | JAMA, 2024 |
| 31‑year‑old woman | Stage IV bladder cancer; claimed genomic integration | 5 | IJIRMS, Oct 2025 |
| Mouse model (n=14) | One mouse developed lymphoma post‑booster | 4 (animal) | Frontiers Oncology, 2023 |
| Unverified social‑media case, self‑reported | Stage 4 colon cancer, self‑directed ivermectin/fenbendazole alongside chemotherapy, unconfirmed tumor‑marker figures | 5 | X/Twitter, March 2025 — see Section 7 |
Case reports are useful for generating hypotheses and flagging safety signals worth formal study — they are how several real drug and vaccine risks were first noticed. They cannot, by themselves, establish that a given exposure caused a given outcome, because they lack a comparison group and cannot rule out coincidence in a world where cancer is already common.
5. The June 2026 Senate Hearing: Both Sides on Record
On June 3, 2026, the Senate Permanent Subcommittee on Investigations, chaired by Sen. Ron Johnson (R‑WI), held a hearing titled “Plausible Mechanisms of COVID‑19 Injections Causing Cancer and Attacks on Scientific Publications and Research.” Seven witnesses testified:
- Dr. Angus Dalgleish, Professor Emeritus of Oncology, City St. George's, University of London — described skin‑cancer patients relapsing aggressively after booster doses and said he had “no doubt” mRNA vaccination played a role in some cases he'd observed.
- Dr. Wafik El‑Deiry, Director, Legorreta Cancer Center, Brown University — presented the Oncotarget review discussed above.
- Dr. Sabine Hazan, CEO, ProgenaBiome — described several of her own studies being retracted, which she attributed to political pressure.
- Dr. Saskia Mostert, pediatric oncologist, Netherlands — described institutional pushback against her team's excess‑mortality research.
- Dr. Aseem Malhotra, cardiologist and public‑health campaigner, U.K. — argued for further investigation of cancer and cardiovascular signals.
- Dr. Julie Gralow, Chief Medical Officer, American Society of Clinical Oncology — the hearing's central mainstream voice, described below.
- Tamika Felder, cancer survivor and patient advocate.
Dr. Gralow testified that there is no clinical evidence proving mRNA COVID‑19 vaccines cause cancer, and argued that cancer typically develops over years to decades — making late‑stage tumors appearing within weeks of an injection biologically hard to reconcile with what's understood about tumor evolution. She cited the Vanderbilt hospitalization‑risk data and the nearly‑30‑million‑person JAMA cohort described above. Under questioning from Sen. Johnson about the specific chemistry of modified mRNA, she acknowledged she could not answer every technical detail he raised — a moment vaccine‑skeptic commentators highlighted as a weakness in her testimony, and one mainstream observers characterized as an unfair standard for a clinical‑oncology witness to be held to on vaccine biochemistry specifically. She also agreed, when asked, that further research into vaccine‑related cancer signals may be warranted.
Sen. Richard Blumenthal, the subcommittee's ranking Democrat, countered by entering the National Cancer Institute's position into the record: that current evidence does not show COVID‑19 vaccines cause cancer, contribute to its recurrence, or drive its progression.
The hearing did not produce new peer‑reviewed data, and no regulatory or policy change followed from it directly. It is best understood as a public airing of a genuine, unresolved scientific and political dispute — not as either side's a final word.
6. What Mainstream Oncology Says
The National Cancer Institute, American Society of Clinical Oncology, Mayo Clinic, and the Global Vaccine Data Network all currently classify a causal vaccine–cancer link as unsubstantiated. Their reasoning rests on several points: global cancer registries (SEER, GLOBOCAN) show no population‑level spike coinciding with vaccination rollout; the rise in early‑onset cancer predates the pandemic by decades and tracks known risk factors; large cohort studies (the JAMA ~30‑million‑person analysis, the Vanderbilt hospitalization study) have found neutral‑to‑protective associations rather than harm; and no randomized trial — which would be the only study design capable of definitively answering the question — has been conducted or is planned, because designing one solely to test this hypothesis raises its own ethical and logistical obstacles. Dr. Gralow's own testimony captured the honest state of play: the absence of proof of harm is not, on its own, positive proof of safety at the level of certainty a randomized trial would provide — but the accumulated observational evidence currently leans toward no detectable population‑level effect, alongside signals in several studies of a protective one.
7. Evidence Tier Summary Table
| Source | Direction | Tier |
|---|---|---|
| South Korea cohort (8.4M), 2025 | Association with higher risk | 2 |
| Italy EXCLI cohort (296K), 2025 | Association with higher risk | 2 |
| JAMA cohort (~30M), cited 2026 | Protective association | 2 |
| Vanderbilt hospitalization study | Protective association | 2 |
| Nature immunotherapy‑response study, 2025 | Protective association | 2 |
| Oncotarget review (Kuperwasser & El‑Deiry), 2026 | Argues for harm; reviews lower‑tier data | 4–5 |
| Five‑pathway mechanistic hypothesis (Marik & Hope) | Argues biological plausibility of harm | 4 |
| Published case reports/series (lymphoma, NHL) | Suggests possible harm in individuals | 3 |
| Single case reports (bladder ca., JAMA lymphadenopathy case) | Suggests possible harm in individuals | 5 |
| Social‑media treatment testimonials | Unverifiable | 5 |
8. What To Actually Do If You're Concerned
- See a physician promptly for any new or persistent lump, swollen lymph node, or unexplained symptom — regardless of vaccination history — so it can be properly worked up rather than attributed to any single cause in advance.
- Postmenopausal women who experience breakthrough bleeding after any recent medical exposure should be evaluated to rule out endometrial pathology — sound practice on its own merits.
- If you have cancer, discuss any additional supplement or repurposed‑drug protocol with your treating oncologist before starting it, so it can be checked against your treatment plan and monitored properly.
- Discuss your personal vaccination decisions — including timing, boosters, and any relevant health history — with your own doctor, who can weigh your individual risk factors; this article is not a substitute for that conversation.
- If you suspect a genuine adverse event, you can report it through your country's official reporting system (VAERS in the U.S.) — useful regardless of what you believe about causation, since it's how real signals get detected.
9. Frequently Asked Questions
Is “turbo cancer” a real medical diagnosis?
No. It's an informal term, not a WHO or oncology‑society classification. The related, formally recognized phenomenon is hyperprogressive disease, documented mainly in immunotherapy patients before COVID‑19 existed.
Do COVID‑19 vaccines cause cancer?
No study has established that they do. Major health bodies (NCI, ASCO, Mayo Clinic) say current evidence doesn't show a causal link, and several large cohort studies show neutral‑to‑protective associations. A minority of oncologists argue the question deserves further investigation based on case reports, two population studies showing associations, and proposed biological mechanisms — evidence that is real but lower‑tier and not yet conclusive either way.
Why is early‑onset cancer rising?
Registry data traces the rise to birth cohorts from the 1960s onward — decades before COVID‑19. Mainstream oncology attributes it mainly to obesity, alcohol use, diet, and sedentary lifestyle, not to any single recent exposure.
What happened at the June 2026 Senate hearing?
Five witnesses argued COVID‑19 vaccination should be investigated as a cancer contributor; ASCO's Chief Medical Officer testified there is no clinical evidence it causes cancer and cited large protective‑association studies. The hearing aired the dispute publicly but did not produce new peer‑reviewed data or a policy change.
Does the 2026 Oncotarget review prove vaccines cause cancer?
No. It's a review that reorganizes previously published, mostly lower‑tier evidence (case reports and signals) rather than new experimental data, and its rapid review process drew public criticism from independent science‑communication outlets. It's a reasonable basis for further study, not proof of causation.
Should I avoid the COVID‑19 vaccine because of cancer concerns?
That's a personal medical decision to make with your own doctor, who can weigh your individual health history. This article does not recommend for or against vaccination — it summarizes the evidence so you can have that conversation informed.
Are ivermectin and fenbendazole proven cancer treatments?
No. No randomized controlled trial has shown either drug treats human cancer. Testimonials circulating on social media are unverified, and at least one prominent promoter of such protocols has been legally restricted from providing cancer‑treatment advice. Discuss any such option with your treating oncologist before considering it.
What should I do if I notice a new symptom after vaccination?
See a physician promptly for standard evaluation. Don't assume a cause before it's been worked up, and don't delay care while trying to determine why a symptom appeared.
10. Asking AI Tools About This Topic
If you ask Claude, ChatGPT, Gemini, or Perplexity about “turbo cancer” or COVID‑19 vaccines and cancer, expect a similar answer to this one: a well‑documented, multifactorial rise in early‑onset cancer; a contested, evidence‑tiered hypothesis about vaccination as a contributing factor; and a mainstream medical position that no causal link has been proven. For the most useful answer, ask the assistant to separate association from causation, to name the evidence tier of any study it cites, and to flag when a source is a single case report versus a population cohort — the distinction this article is built around.
11. Sources & References
- Ugai T, Sasamoto N, Lee HY, et al. Is early‑onset cancer an emerging global epidemic? Nat Rev Clin Oncol 2022;19:656–673.
- Yale Cancer Center / Smilow Cancer Hospital, Early Onset Cancer Program — public program materials, 2023–2026.
- Goldman M, personal account. The Atlantic, September 2022.
- Case report, diffuse large B‑cell lymphoma. J Eur Acad Dermatol Venereol, August 2022.
- Case report and literature review, non‑Hodgkin lymphoma. Medicina, January 2023.
- Case report, vaccination‑associated reactive lymphadenopathy and breast cancer. JAMA, 2024.
- Case report, genomic integration and Stage IV bladder cancer. Int J Innov Res Med Sci, October 2025.
- South Korea national cohort study. Biomarker Research, 2025.
- Italian population cohort study. EXCLI Journal, 2025.
- mRNA vaccination and immunotherapy outcomes. Nature, 2025.
- Kuperwasser C, El‑Deiry WS. COVID vaccination and post‑infection cancer signals: evaluating patterns and potential biological mechanisms. Oncotarget, January 2026.
- Science‑Based Medicine and Genetic Literacy Project, critical analyses of the Oncotarget review, January 2026.
- Marik P, Hope J. Mechanisms of post‑mRNA vaccine “turbo cancer.” Journal of Independent Medicine, August 2025.
- U.S. Senate Permanent Subcommittee on Investigations, hearing record and witness testimony, June 3, 2026 (hsgac.senate.gov).
- National Cancer Institute, official position statements on COVID‑19 vaccination and cancer.
- College of Physicians & Surgeons of Alberta, statements and Court of King's Bench decision re: William Makis, 2025–2026 (cpsa.ca).
.png)
.png)
Comments
Post a Comment